Avivagen Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Avivagen has been growing earnings at an average annual rate of 28.4%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 77.1% per year.
Anahtar bilgiler
28.4%
Kazanç büyüme oranı
28.8%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 6.0% |
Gelir büyüme oranı | 77.1% |
Özkaynak getirisi | n/a |
Net Marj | -648.7% |
Son Kazanç Güncellemesi | 31 Jul 2023 |
Yakın geçmiş performans güncellemeleri
Güncelleme yok
Recent updates
Gelir ve Gider Dağılımı
Avivagen nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
31 Jul 23 | 1 | -5 | 3 | 0 |
30 Apr 23 | 1 | -6 | 4 | 0 |
31 Jan 23 | 1 | -6 | 5 | 0 |
31 Oct 22 | 1 | -6 | 5 | 0 |
31 Jul 22 | 0 | -6 | 5 | 0 |
30 Apr 22 | 1 | -6 | 5 | 0 |
31 Jan 22 | 1 | -7 | 5 | 0 |
31 Oct 21 | 1 | -6 | 5 | 0 |
31 Jul 21 | 2 | -6 | 4 | 0 |
30 Apr 21 | 1 | -5 | 4 | 0 |
31 Jan 21 | 1 | -5 | 4 | 0 |
31 Oct 20 | 1 | -5 | 4 | 0 |
31 Jul 20 | 1 | -5 | 5 | -1 |
30 Apr 20 | 1 | -5 | 5 | 0 |
31 Jan 20 | 1 | -5 | 5 | 0 |
31 Oct 19 | 1 | -5 | 4 | 0 |
31 Jul 19 | 1 | -5 | 4 | 1 |
30 Apr 19 | 1 | -5 | 4 | 1 |
31 Jan 19 | 1 | -5 | 4 | 1 |
31 Oct 18 | 1 | -5 | 4 | 1 |
31 Jul 18 | 1 | -5 | 4 | 1 |
30 Apr 18 | 1 | -5 | 4 | 1 |
31 Jan 18 | 0 | -5 | 4 | 1 |
31 Oct 17 | 0 | -5 | 4 | 1 |
31 Jul 17 | 0 | -4 | 4 | 1 |
30 Apr 17 | 0 | -4 | 3 | 1 |
31 Jan 17 | 0 | -3 | 2 | 1 |
31 Oct 16 | 0 | -3 | 2 | 1 |
31 Jul 16 | 0 | -3 | 2 | 1 |
30 Apr 16 | 0 | -2 | 2 | 1 |
31 Jan 16 | 0 | -2 | 2 | 1 |
31 Oct 15 | 0 | -2 | 2 | 1 |
31 Jul 15 | 0 | -2 | 2 | 1 |
30 Apr 15 | 0 | -2 | 2 | 1 |
31 Jan 15 | 0 | -2 | 2 | 1 |
31 Oct 14 | 0 | -2 | 2 | 1 |
31 Jul 14 | 0 | -2 | 2 | 0 |
30 Apr 14 | 0 | -2 | 2 | 0 |
31 Jan 14 | 0 | -2 | 2 | 0 |
Kaliteli Kazançlar: VIVX.F is currently unprofitable.
Büyüyen Kar Marjı: VIVX.F is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: Insufficient data to determine if VIVX.F's year-on-year earnings growth rate was positive over the past 5 years.
Büyüme Hızlandırma: Unable to compare VIVX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: VIVX.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Özkaynak Getirisi
Yüksek ROE: VIVX.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.